Beiley Biofund Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	1,126	96.51	88.62
Depreciation & Amortization	2.54	1.85	0.18
Loss (Gain) From Sale of Investments	-1,227	-146.66	-138.39
Other Operating Activities	24.57	13.48	-12.37
Change in Accounts Receivable	-7.1	-	-0.18
Change in Accounts Payable	38.65	33.13	0.23
Change in Other Net Operating Assets	26.64	62.93	-127.44
Operating Cash Flow	-35.32	217.94	-567.9
Capital Expenditures	-0.08	-1.37	-1.12
Sale (Purchase) of Intangibles	-0.35	-0.07	-
Investment in Securities	390	-300	-494.5
Other Investing Activities	-	-	-0.28
Investing Cash Flow	389.57	-301.44	-495.9
Long-Term Debt Repaid	-1.06	-1.04	-0.17
Net Debt Issued (Repaid)	-1.06	-1.04	-0.17
Issuance of Common Stock	-	-	1,680
Repurchase of Common Stock	-	-	-261.89
Common Dividends Paid	-30.79	-	-
Financing Cash Flow	-31.85	-1.04	1,418
Net Cash Flow	322.4	-84.54	354.13
Free Cash Flow	-35.4	216.57	-569.02
Free Cash Flow Margin	-2.89%	154.10%	-407.90%
Free Cash Flow Per Share	-0.17	1.05	-6.30
Cash Interest Paid	0.01	0.04	0.01
Cash Income Tax Paid	22.53	1.5	10.87
Levered Free Cash Flow	779.57	102.56	-
Unlevered Free Cash Flow	779.58	102.58	-
Change in Working Capital	39.34	252.76	-505.94